Covalent inhibitors of the SW-II pocket have been approved for clinical trials in humans, and recently, the Food and Drug Administration (FDA) has approved sotorasib [38] and adagrasib [39] for the treatment of advanced non-small cell lung cancer (NSCLC) patients harboring the KRAS G12C mutation. Here, KRAS is linked to non-small cell lung carcinoma.